As of this morning, there were two regular abstracts listed for apabetalone or BETonMACE to be presented at ESC 2019. Only titles are available right now. You can search here in the program planner.

Mon Sept 2, 2019, 14:00: BET-inhibition with Apabetalone in Post-ACS Patients with Diabetes: Design and Baseline Characteristics of the BETonMACE trial

Tues Sept 3, 2019, 08:30: Apabetalone (RVX-208) inhibits key drivers of vascular inflammation, calcification, and plaque vulnerability through a BET-dependent epigenetic mechanism

My guess is that the title/abstract related to BETonMACE above is kind of a placeholder that was submitted during the normal abstract application process. My guess is that it would be withdrawn IF BETonMACE gets a later breaker, consistent with what is described in the late breaker submission guidelines.

On a side note, I did ask IR "Is Resverlogix and/or the BETonMACE clinical steering committee planning to publish a BETonMACE study rationale and design paper in advance of the top-line data announcement?" and they replied "Yes, the goal is to publish a design paper prior to top line read-out. More information to come in due course."

BearDownAZ